Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -83.25% | -54.73% | -46.68% | -6.23% | 9.31% |
| Total Depreciation and Amortization | -13.71% | -3.13% | -13.43% | 96.01% | 8.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.21% | 55.95% | 69.97% | 80.21% | 49.30% |
| Change in Net Operating Assets | 786.03% | -8.46% | 158.40% | -52.89% | -31.37% |
| Cash from Operations | -32.30% | -45.16% | -28.25% | -17.29% | 12.00% |
| Capital Expenditure | 95.54% | -- | 58.26% | -- | -1,327.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.64% | 116.00% | 66.96% | -- | -1,327.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,304.97% | -- | 1,132.14% | -75.00% | -49.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,304.97% | -- | 227.31% | -75.00% | 159.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.31% | -172.30% | -22.88% | -19.86% | 14.22% |